NAV3 and Alzheimer disease: Consistently, using the Agora database, we discovered that NAV3 had a significantly lower level of expression in DLPFC (p = 0.02) and temporal cortex region (TCX) (p = 8.7×10− 6) among AD cases compared with normal controls (Fig. 4E).